Is Medicamen Organ. overvalued or undervalued?

As of 3 November 2025, the valuation grade for Medicamen Organ. has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 11.43, an EV to EBITDA ratio of 8.33, and a ROCE of 12.71%. In comparison to its peers, Sun Pharma. has a significantly higher PE ratio of 35.62, indicating it is expensive, while Cipla is rated attractive with a PE of 22.44. Despite the recent adjustment in valuation, Medicamen Organ. has underperformed relative to the Sensex, with a year-to-date return of -40.72% compared to the Sensex's 8.96%. This underperformance, combined with its fair valuation, suggests that while the stock may not be undervalued, it is not currently positioned for significant upside in the near term.